Society for Immunotherapy of Cancer (SITC), shared on LinkedIn:
“Back at the EU Immuno-Oncology Drug Development Summit, we’re now tackling a critical piece of the drug development puzzle: regulation.
Experts from the FDA, EMA, Swissmedic, academia, and industry are discussing global regulatory perspectives, clinical trial design, and how we can create pathways that support innovation while maintaining rigorous standards.
At the SITC EU Immuno-Oncology Drug Development Summit, we’re turning our attention to antibody-drug conjugates.
The discussion is covering B7-H3, immune payloads, and ADC–IO combinations, including their potential to transform treatment in difficult disease settings.”
Other articles about Immuno-Oncology on OncoDaily.